The Systemic Lupus Erythematosus market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Systemic Lupus Erythematosus: An Overview
According to the American College of Rheumatology “Systemic lupus erythematosus, ( SLE, Lupus) is a chronic (long-term) disease that causes systemic inflammation which affects multiple organs. In addition to affecting the skin and joints, it can affect other organs in the body such as the kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain.
Many patients experience fatigue, weight loss, and fever. Lupus flares vary from mild to severe. SLE is most commonly seen in women in the reproductive age group (frequently starting at childbearing age), although lupus is increasingly recognized after the age of 40 years, particularly in the Europeans.
The diagnosis of systemic lupus erythematosus is based on clinical and laboratory criteria, however, SLE is difficult to diagnose in primary care because many of the symptoms (e.g., fatigue, rash, joint pain) are nonspecific and overlap with those of more common conditions. Furthermore, biomarkers are often negative or normal, early in the course of the illness. The most common presenting symptoms are constitutional, such as fatigue, weight loss, and fever without a focal infection, occurring in up to 90% of patients.
Systemic Lupus Erythematosus Market Key Facts
As per DelveInsight estimates, the total diagnosed prevalent cases of Systemic Lupus Erythematosus in the 7MM was found to be 484,200+ cases in 2017. Among all the countries, the estimates show a higher population of Systemic Lupus Erythematosus in the United States with 259,400+ cases in 2017.
Among the EU5 countries, the UK had the highest diagnosed prevalent population of Systemic Lupus Erythematosus with 62,800+ cases, followed by Italy in 2017. On the other hand, Spain had the lowest prevalent population.
Females are more prone to SLE than males in all 7MM countries.
Systemic Lupus Erythematosus Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Systemic Lupus Erythematosus market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives complete detail of the Systemic Lupus Erythematosus market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), and competition with other therapies, brand value, and their impact on the market.
Systemic Lupus Erythematosus Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.
Systemic Lupus Erythematosus Epidemiology Subtype Segmentation
Total Diagnosed Prevalent cases of Systemic Lupus Erythematosus
Gender-Specific cases of Systemic Lupus Erythematosus
Severity-Specific cases of Systemic Lupus Erythematosus
Treatable cases of Systemic Lupus Erythematosus
Systemic Lupus Erythematosus Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Systemic Lupus Erythematosus market or expected to get launched during the study period. The analysis covers Systemic Lupus Erythematosus market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Systemic Lupus Erythematosus Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Request for Sample PDF Report – https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-market
Systemic Lupus Erythematosus Therapeutics Analysis
The Systemic Lupus Erythematosus market dynamics is anticipated to change in the coming years owing to the expected launch of emerging therapies during the forecasted period.
Some of the key companies in the Systemic Lupus Erythematosus Market include:
AstraZeneca
ImmuPharma
Eli Lilly
Janssen Pharmaceutical
Merck KGaA
ILTOO Pharma
Biogen
Celgene
UCB Pharma/Biogen
Neovacs
Idorsia Pharmaceuticals
Kezar Life Sciences
Bristol-Myers Squibb
Xencor
And others
Systemic Lupus Erythematosus Therapies covered in the report include:
Anifrolumab
Lupuzor
Baricitinib
Stelara
Atacicept
XmAb5871
Lulizumab pegol
Cenerimod
IFNα Kinoid
Dapirolizumab pegol
CC-220
BIIB059
ILT-101
KZR-616
And many more.
Get More Detailed Insights Into the Emerging Therapies & Key Companies – https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Systemic Lupus Erythematosus Competitive Intelligence Analysis
4. Systemic Lupus Erythematosus Market Overview at a Glance
5. Systemic Lupus Erythematosus Disease Background and Overview
6. Systemic Lupus Erythematosus Patient Journey
7. Systemic Lupus Erythematosus Epidemiology and Patient Population
8. Systemic Lupus Erythematosus Treatment Algorithm, Current Treatment, and Medical Practices
9. Systemic Lupus Erythematosus Unmet Needs
10. Key Endpoints of Systemic Lupus Erythematosus Treatment
11. Systemic Lupus Erythematosus Marketed Products
12. Systemic Lupus Erythematosus Emerging Therapies
13. Systemic Lupus Erythematosus Seven Major Market Analysis
14. Attribute Analysis
15. Systemic Lupus Erythematosus Market Outlook (7 major markets)
16. Systemic Lupus Erythematosus Access and Reimbursement Overview
17. KOL Views on the Systemic Lupus Erythematosus Market.
18. Systemic Lupus Erythematosus Market Drivers
19. Systemic Lupus Erythematosus Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF Report – https://www.delveinsight.com/sample-request/systemic-lupus-erythematosus-market
About DelveInsightDelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
US Healthcare Outlook ReportThe US is the headquarters of several major pharmaceutical and medical device companies in the world. Due to this, the U.S. pharmaceutical market is the world’s most important national market. The US alone holds over 45 % of the global pharmaceutical market. Healthcare coverage in the US is provided through a combination of private health insurance and public health coverage. The two most important healthcare coverage plans in the US are Medicare and Medicaid.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Shruti ThakurEmail: Send EmailPhone: 09650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
